Saturna Capital Corp Purchases 376,164 Shares of Kenvue Inc. (NYSE:KVUE)

Saturna Capital Corp lifted its position in shares of Kenvue Inc. (NYSE:KVUE) by 28.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,711,024 shares of the company’s stock after acquiring an additional 376,164 shares during the period. Saturna Capital Corp owned approximately 0.09% of Kenvue worth $36,530,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the business. Moors & Cabot Inc. lifted its holdings in shares of Kenvue by 2.4% during the fourth quarter. Moors & Cabot Inc. now owns 184,528 shares of the company’s stock valued at $3,940,000 after purchasing an additional 4,327 shares in the last quarter. King Luther Capital Management Corp raised its position in Kenvue by 286.5% in the 4th quarter. King Luther Capital Management Corp now owns 207,367 shares of the company’s stock worth $4,427,000 after buying an additional 153,715 shares during the last quarter. Citizens Financial Group Inc. RI bought a new position in Kenvue during the 4th quarter valued at about $229,000. Daiwa Securities Group Inc. boosted its holdings in shares of Kenvue by 7.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 272,497 shares of the company’s stock valued at $5,818,000 after acquiring an additional 19,042 shares during the last quarter. Finally, Saybrook Capital NC grew its stake in shares of Kenvue by 6.2% in the fourth quarter. Saybrook Capital NC now owns 323,480 shares of the company’s stock worth $6,906,000 after acquiring an additional 18,783 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Trading Down 1.7 %

Shares of NYSE:KVUE opened at $23.50 on Wednesday. The stock has a 50 day moving average of $21.74 and a 200 day moving average of $22.36. The company has a market cap of $44.92 billion, a PE ratio of 44.35, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.49%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 154.72%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on KVUE. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Piper Sandler increased their price target on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Barclays cut their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Citigroup reduced their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Finally, Canaccord Genuity Group raised their target price on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus target price of $23.75.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.